Excelsior Biopharma Asset Resilience Ratio
Excelsior Biopharma asset resilience ratio. Excelsior Biopharma (6496) has an Asset Resilience Ratio of 0.81% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6496 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Excelsior Biopharma (2017–2024)
Asset resilience ratio of Excelsior Biopharma from 2017 to 2024. This chart shows how Excelsior Biopharma's Asset Resilience Ratio has changed over time. Read 6496 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Excelsior Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Excelsior Biopharma.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$11.45 Million | 0.81% |
| Total Liquid Assets | NT$11.45 Million | 0.81% |
Asset Resilience Insights
- Limited Liquidity: Excelsior Biopharma maintains only 0.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Excelsior Biopharma Industry Peers by Asset Resilience Ratio
Compare Excelsior Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Excelsior Biopharma Asset Resilience Ratio by Year (2017–2024)
Excelsior Biopharma asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for Excelsior Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.73% | NT$11.45 Million ≈ $360.58K |
NT$1.58 Billion ≈ $49.73 Million |
-11.59pp |
| 2022-12-31 | 12.31% | NT$211.19 Million ≈ $6.65 Million |
NT$1.71 Billion ≈ $54.03 Million |
+11.72pp |
| 2020-12-31 | 0.59% | NT$11.22 Million ≈ $353.52K |
NT$1.90 Billion ≈ $59.87 Million |
-0.07pp |
| 2018-12-31 | 0.66% | NT$10.80 Million ≈ $340.23K |
NT$1.64 Billion ≈ $51.80 Million |
+0.65pp |
| 2017-12-31 | 0.00% | NT$34.00K ≈ $1.07K |
NT$1.68 Billion ≈ $52.90 Million |
-- |
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more